Rodriguez-Roisin Roberto, Tetzlaff Kay, Watz Henrik, Wouters Emiel Fm, Disse Bernd, Finnigan Helen, Magnussen Helgo, Calverley Peter Ma
Respiratory Institute, Servei de Pneumologia, Hospital Clínic IDIBAPS-CIBERES, Universitat de Barcelona, Barcelona, Spain.
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; Department of Sports Medicine, University of Tübingen, Tübingen, Germany.
Int J Chron Obstruct Pulmon Dis. 2016 Aug 22;11:1973-81. doi: 10.2147/COPD.S106142. eCollection 2016.
The WISDOM study (NCT00975195) reported a change in lung function following withdrawal of fluticasone propionate in patients with severe to very severe COPD treated with tiotropium and salmeterol. However, little is known about the validity of home-based spirometry measurements of lung function in COPD. Therefore, as part of this study, following suitable training, patients recorded daily home-based spirometry measurements in addition to undergoing periodic in-clinic spirometric testing throughout the study duration. We subsequently determined the validity of home-based spirometry for detecting changes in lung function by comparing in-clinic and home-based forced expiratory volume in 1 second in patients who underwent stepwise fluticasone propionate withdrawal over 12 weeks versus patients remaining on fluticasone propionate for 52 weeks. Bland-Altman analysis of these data confirmed good agreement between in-clinic and home-based measurements, both across all visits and at the individual visits at study weeks 6, 12, 18, and 52. There was a measurable difference between the forced expiratory volume in 1 second values recorded at home and in the clinic (mean difference of -0.05 L), which may be due to suboptimal patient effort in performing unsupervised recordings. However, this difference remained consistent over time. Overall, these data demonstrate that home-based and in-clinic spirometric measurements were equally valid and reliable for assessing lung function in patients with COPD, and suggest that home-based spirometry may be a useful tool to facilitate analysis of changes in lung function on a day-to-day basis.
WISDOM研究(NCT00975195)报告称,在接受噻托溴铵和沙美特罗治疗的重度至极重度慢性阻塞性肺疾病(COPD)患者中,停用丙酸氟替卡松后肺功能发生了变化。然而,对于COPD患者在家中进行肺功能的肺活量测定的有效性知之甚少。因此,作为本研究的一部分,在经过适当培训后,患者除了在整个研究期间定期进行门诊肺活量测定外,还记录每日在家中的肺活量测定结果。随后,我们通过比较在12周内逐步停用丙酸氟替卡松的患者与继续使用丙酸氟替卡松52周的患者的门诊和家庭一秒用力呼气量,来确定家庭肺活量测定对检测肺功能变化的有效性。对这些数据进行的布兰德-奥特曼分析证实,在所有就诊时以及在研究第6、12、18和52周的个体就诊时,门诊和家庭测量之间都有良好的一致性。在家中和门诊记录的一秒用力呼气量值之间存在可测量的差异(平均差异为-0.05L),这可能是由于患者在进行无人监督的记录时努力程度欠佳所致。然而,这种差异随时间保持一致。总体而言,这些数据表明,家庭和门诊肺活量测定在评估COPD患者的肺功能方面同样有效且可靠,并表明家庭肺活量测定可能是促进日常肺功能变化分析的有用工具。